Saptagir Labs & Jubilant Generics Collaborate

Saptagir Labs & Jubilant Generics Collaborate to Manufacture Remdesivir

An exclusive agreement with a Jubilant Life Sciences company, Jubilant Generics was announced by Saptagir Laboratories – part of the Saptagir Group for manufacturing active pharma ingredients and intermediates for remdesivir, an intravenously administered drug.

At Saptagir Laboratories’ Hyderabad WHO GMP certified sterile drug product manufacturing plant, the drug will be produced.

The Promoter and MD of Saptagir Laboratories, Shilpa Reddy, said, “It is our honor to join hands with Jubilant Generics and take a significant step towards saving millions of lives affected by the pandemic by making this life-saving therapy available to patients across countries. Along with our array of products targeted at the fast-growing health and wellness segment, there will be new revenue streams opened with our foray into bulk drug manufacturing, backed by our extensive global customer base spanning in over more than 50 countries.”

The Promoter & Chairman of Saptagir Group, Mahesh Reddy said, “In the product development with molecules that were manufactured in only China previously, we have had several successes. The need for India to emerge as a strong second source for products beyond China is met by this partnership. We will further grow our presence in the health and wellness business with the new investment of Rs 75 crores in the pharma plant at Hyderabad.”

See Also
R-Pharm's COVID-19 Drug Gets Russia's Approval For Sale In Pharmacies

As a course of treatment for COVID-19, Gilead Sciences developed remdesivir as an experimental antiviral drug. For distribution to 127 countries, a non-exclusive licensing agreement was signed by Gilead with Jubilant Life Sciences. After this deal, in order to manufacture remdesivir, an exclusive agreement with Saptagir Laboratories was signed by Jubilant Life Sciences through its subsidiary Jubilant Generics.

According to Gilead Life Sciences, the holder of the patent, the market for remdesivir this year is estimated to be $2.3 billion, and the fiscal year based upon their understanding of the situation.

Saptagir Labs & Jubilant Generics Collaborate to Manufacture Remdesivir

Upload your CV to Rasayanika Talent Pool


Please enter your comment!
Please enter your name here